Immunobiology of Ebola and Lassa virus infections

Nature Reviews Immunology

Volumn 17, Issue 3, 2017, Pages 195-207

  Prescott, Joseph B ^a   Marzi, Andrea ^a   Safronetz, David ^b,c   Robertson, Shelly J ^a   Feldmann, Heinz ^a,c   Best, Sonja M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; DISEASE COURSE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOBIOLOGY; INNATE IMMUNITY; LASSA FEVER; LASSA VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS LIKE AGENT; VIRUS REPLICATION; IMMUNOLOGY;

EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LASSA FEVER; LASSA VIRUS;

EID: 85010211027     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2016.138     Document Type: Review

References (140)

1. Paessler, S., Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 8, 411-440 (2013
2. Baize, S., et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418-1425 (2014
3. Feldmann, F., Sanchez, A., Geisbert, T. W. in Fields Virology 6th edn (eds M Knipe, D., Howley, P. M. ) 923-956 (Lippincott Williams and Wilkins, 2013
4. Kuhn, J. H., et al. in Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses (eds King, A. M. Q., Adams, M. J., Carstens, E. B., Lefkowitz, E. J. ) 665-671 (Elsevier/Academic Press, 2011
5. Frame, J. D., Baldwin, J. M. Jr, Gocke, D. J., Troup, J. M. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am. J. Trop. Med. Hyg. 19, 670-676 (1970
6. Fichet-Calvet, E., Rogers, D. J. Risk maps of Lassa fever in West Africa. PLoS Negl. Trop. Dis. 3, e388 (2009
7. Sogoba, N., Feldmann, H., Safronetz, D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health 59 (Suppl. 2), 43-47 (2012
8. Ogbu, O., Ajuluchukwu, E., Uneke, C. J. Lassa fever in West African sub-region: an overview. J. Vector Borne Dis. 44, 1-11 (2007
9. Paweska, J. T., et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg. Infect. Dis. 15, 1598-1602 (2009
10. Fisher-Hoch, S. P., et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 311, 857-859 (1995
11. Geisbert, T. W., Strong, J. E., Feldmann, H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J. Infect. Dis. 212 (Suppl. 2), S91-S97 (2015
12. Smith, D. R., Holbrook, M. R., Gowen, B. B. Animal models of viral hemorrhagic fever. Antiviral Res. 112, 59-79 (2014
13. Cheng, Y., et al. Principles of regulatory information conservation between mouse and human. Nature 515, 371-375 (2014)
14. Chertow, D. S., et al. Ebola virus disease in West Africa-clinical manifestations and management. N. Engl. J. Med. 371, 2054-2057 (2014
15. Schieffelin, J. S., et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med. 371, 2092-2100 (2014
16. Mattia, J. G., et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect. Dis. 16, 331-338 (2016
17. Tiffany, A., et al. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin. Infect. Dis. 62, 1360-1366 (2016
18. Caluwaerts, S., et al. Dilemmas in managing pregnant women with Ebola: 2 case reports. Clin. Infect. Dis. 62, 903-905 (2016
19. Mupapa, K., et al. Ebola hemorrhagic fever and pregnancy. J. Infect. Dis. 179 (Suppl. 1), S11-S12 (1999
20. Bausch, D. G., et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis. 1, 269-281 (2001
21. Frame, J. D. Clinical features of Lassa fever in Liberia. Rev. Infect. Dis. 11 (Suppl. 4), S783-S789 (1989
22. McCormick, J. B., Fisher-Hoch, S. P. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75-109 (2002
23. Gunther, S., Lenz, O. Lassa virus. Crit. Rev. Clin. Lab. Sci. 41, 339-390 (2004
24. Qiu, X., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014
25. Sissoko, D., et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 13, e1001967 (2016
26. Henao-Restrepo, A. M., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015
27. Geisbert, T. W., et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163, 2347-2370 (2003
28. Ryabchikova, E. I., Kolesnikova, L. V., Luchko, S. V. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179 (Suppl. 1), S199-S202 (1999
29. Walker, D. H., Wulff, H., Lange, J. V., Murphy, F. A. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 52, 523-534 (1975
30. Banadyga, L., Dolan, M. A., Ebihara, H. Rodent-adapted filoviruses and the molecular basis of pathogenesis. J. Mol. Biol. 428, 3449-3466 (2016
31. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651-661 (1998
32. Ebihara, H., et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2, e73 (2006
33. Ebihara, H., et al. A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. J. Infect. Dis. 207, 306-318 (2013
34. Gibb, T. R., et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125, 233-242 (2001
35. Baize, S., et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172, 2861-2869 (2004
36. Baize, S., et al. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 8, 1194-1202 (2006
37. Bowen, M. D., Peters, C. J., Nichol, S. T. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol. Phylogenet. Evol. 8, 301-316 (1997
38. Fisher-Hoch, S. P., Hutwagner, L., Brown, B., McCormick, J. B. Effective vaccine for lassa fever. J. Virol. 74, 6777-6783 (2000
39. Hawiger, D., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001
40. Mahanty, S., et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170, 2797-2801 (2003
41. Stroher, U., et al. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75, 11025-11033 (2001
42. Schneider, W. M., Chevillotte, M. D., Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513-545 (2014
43. Brannan, J. M., et al. Interferon alpha/beta receptor-deficient mice as a model for Ebola virus disease. J. Infect. Dis. 212 (Suppl. 2), S282-S294 (2015
44. Bray, M. The role of the type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 1365-1373 (2001
45. Oestereich, L., et al. Chimeric mice with competent hematopoietic immunity reproduce key features of severe Lassa fever. PLoS Pathog. 12, e1005656 (2016
46. Yun, N. E., et al. Functional interferon system is required for clearance of lassa virus. J. Virol. 86, 3389-3392 (2012
47. Baize, S., et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83, 5890-5903 (2009
48. Jouvenet, N., et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83, 1837-1844 (2009
49. Sakuma, T., Noda, T., Urata, S., Kawaoka, Y., Yasuda, J. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83, 2382-2385 (2009
50. Messaoudi, I., Amarasinghe, G. K., Basler, C. F. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13, 663-676 (2015
51. Chan, Y. K., Gack, M. U. RIG-I-like receptor regulation in virus infection and immunity. Curr. Opin. Virol. 12, 7-14 (2015
52. MacMicking, J. D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 12, 367-382 (2012
53. Versteeg, G. A., Garcia-Sastre, A. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 13, 508-516 (2010
54. Basler, C. F., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl Acad. Sci. USA 97, 12289-12294 (2000
55. Cardenas, W. B., et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80, 5168-5178 (2006
56. Hartman, A. L., Towner, J. S., Nichol, S. T. A. C-Terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328, 177-184 (2004
57. Leung, D. W., et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17, 165-172 (2010
58. Luthra, P., et al. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe 14, 74-84 (2013
59. Prins, K. C., Cardenas, W. B., Basler, C. F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKK and TBK-1. J. Virol. 83, 3069-3077 (2009
60. Chang, T. H., et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5, e1000493 (2009
61. Kubota, T., et al. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 283, 25660-25670 (2008
62. Yen, B. C., Basler, C. F. Effects of filovirus interferon antagonists on responses of human monocyte-derived dendritic cells to RNA virus infection. J. Virol. 90, 5108-5118 (2016
63. Reid, S. P., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80, 5156-5167 (2006
64. Reid, S. P., Valmas, C., Martinez, O., Sanchez, F. M., Basler, C. F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 81, 13469-13477 (2007
65. Xu, W., et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16, 187-200 (2014
66. Hartman, A. L., et al. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of Ebola virus. J. Virol. 82, 2699-2704 (2008
67. Prins, K. C., et al. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 84, 3004-3015 (2010
68. Carrera Silva, E. A., et al. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 39, 160-170 (2013
69. Lemke, G. Biology of the TAM receptors. Cold Spring Harb. Perspect. Biol. 5, a009076 (2013
70. Freeman, G. J., Casasnovas, J. M., Umetsu, D. T., DeKruyff, R. H. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 235, 172-189 (2010
71. Richard, A. S., et al. Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc. Natl Acad. Sci. USA 112, 14682-14687 (2015
72. Dahlmann, F., et al. Analysis of Ebola virus entry into macrophages. J. Infect. Dis. 212 (Suppl. 2), S247-S257 (2015
73. Bhattacharyya, S., et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14, 136-147 (2013
74. Okumura, A., Pitha, P. M., Yoshimura, A., Harty, R. N. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J. Virol. 84, 27-33 (2010)
75. Okumura, A., et al. Suppressor of cytokine signaling 3 is an inducible host factor that regulates virus egress during Ebola virus infection. J. Virol. 89, 10399-10406 (2015
76. Feng, Z., Cerveny, M., Yan, Z., He, B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 81, 182-192 (2007
77. Schumann, M., Gantke, T., Muhlberger, E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83, 8993-8997 (2009
78. Gustin, J. K., Bai, Y., Moses, A. V., Douglas, J. L. Ebola virus glycoprotein promotes enhanced viral egress by preventing Ebola VP40 from associating with the host restriction factor BST2/tetherin. J. Infect. Dis. 212 (Suppl. 2), S181-S190 (2015
79. Kaletsky, R. L., Francica, J. R., Agrawal-Gamse, C., Bates, P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl Acad. Sci. USA 106, 2886-2891 (2009
80. Vande Burgt, N. H., Kaletsky, R. L., Bates, P. Requirements within the Ebola viral glycoprotein for tetherin antagonism. Viruses 7, 5587-5602 (2015
81. Xing, J., Ly, H., Liang, Y. The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production. J. Virol. 89, 2944-2955 (2015
82. Hastie, K. M., King, L. B., Zandonatti, M. A., Saphire, E. O. Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease. PLoS ONE 7, e44211 (2012
83. Jiang, X., et al. Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppression. J. Biol. Chem. 288, 16949-16959 (2013
84. Pythoud, C., et al. Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKK. J. Virol. 86, 7728-7738 (2012
85. Rodrigo, W. W., et al. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J. Virol. 86, 8185-8197 (2012
86. Shimojima, M., Stroher, U., Ebihara, H., Feldmann, H., Kawaoka, Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J. Virol. 86, 2067-2078 (2012
87. Geisbert, T. W., et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80, 171-186 (2000
88. Reed, D. S., Hensley, L. E., Geisbert, J. B., Jahrling, P. B., Geisbert, T. W. Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques. Viral Immunol. 17, 390-400 (2004
89. Wauquier, N., Becquart, P., Padilla, C., Baize, S., Leroy, E. M. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4, e837 (2010
90. Paulsen, M., Janssen, O. Pro-and anti-apoptotic CD95 signaling in T cells. Cell. Commun. Signal. 9, 7 (2011
91. McElroy, A. K., et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl Acad. Sci. USA 112, 4719-4724 (2015
92. Baize, S., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5, 423-426 (1999
93. Baize, S., et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128, 163-168 (2002
94. Schroder, K., Hertzog, P. J., Ravasi, T., Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163-189 (2004
95. Villinger, F., et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-associated with fatal Ebola virus infection. J. Infect. Dis. 179 (Suppl. 1), S188-S191 (1999
96. Hutchinson, K. L., Rollin, P. E. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J. Infect. Dis. 196 (Suppl. 2), S357-S363 (2007
97. Couper, K. N., Blount, D. G., Riley, E. M. IL-10: the master regulator of immunity to infection. J. Immunol. 180, 5771-5777 (2008
98. Fiorentino, D. F., Bond, M. W., Mosmann, T. R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081-2095 (1989
99. Ouyang, J., et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe 16, 616-626 (2014
100. Panchal, R. G., et al. Induced IL-10 splice altering approach to antiviral drug discovery. Nucleic Acid. Ther. 24, 179-185 (2014
101. Leroy, E. M., Baize, S., Debre, P., Lansoud-Soukate, J., Mavoungou, E. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol. 124, 453-460 (2001
102. Arend, W. P. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13, 323-340 (2002
103. Ruibal, P., et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100-104 (2016
104. Gunther, S., et al. Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions. Med. Microbiol. Immunol. 189, 225-229 (2001
105. Geisbert, T. W., et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005
106. Zhou, X., Ramachandran, S., Mann, M., Popkin, D. L. Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. Viruses 4, 2650-2669 (2012
107. Meulen, J., et al. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321, 134-143 (2004
108. ter Meulen, J., et al. Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J. Virol. 74, 2186-2192 (2000
109. Pannetier, D., et al. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J. Virol. 85, 8293-8306 (2011
110. Kiley, M. P., Lange, J. V., Johnson, K. M. Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2, 738 (1979
111. Jahrling, P. B., et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 11, 135-140 (1996
112. Jahrling, P. B., et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179 (Suppl. 1), S224-S234 (1999
113. Marzi, A., et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7, e36192 (2012
114. Mupapa, K., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179 (Suppl. 1), S18-S23 (1999
115. van Griensven, J., et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374, 33-42 (2016
116. Oswald, W. B., et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007
117. Parren, P. W., Geisbert, T. W., Maruyama, T., Jahrling, P. B., Burton, D. R. Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76, 6408-6412 (2002
118. Olinger, G. G. Jr et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl Acad. Sci. USA 109, 18030-18035 (2012
119. Pettitt, J., et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl Med. 5, 199ra113 (2013
120. Lyon, G. M., et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371, 2402-2409 (2014
121. Corti, D., et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339-1342 (2016
122. Leroy, E. M., et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355, 2210-2215 (2000
123. Marzi, A., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893-1898 (2013
124. Johnson, K. M., et al. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155, 456-464 (1987
125. Robinson, J. E., et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016
126. Schountz, T., et al. Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus. Proc. Natl Acad. Sci. USA 104, 15496-15501 (2007
127. Basler, C. F. Innate immune evasion by filoviruses. Virology 479-480, 122-130 (2015
128. Hoenen, T., Feldmann, H. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev. Anti Infect. Ther. 12, 1253-1263 (2014
129. Martins, K. A., Jahrling, P. B., Bavari, S., Kuhn, J. H. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev. Vaccines 15, 1101-1112 (2016
130. Marzi, A., Feldmann, F., Geisbert, T. W., Feldmann, H., Safronetz, D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg. Infect. Dis. 21, 305-307 (2015
131. Mire, C. E., Geisbert, T. W., Feldmann, H., Marzi, A. Ebola virus vaccines-reality or fiction Expert Rev. Vaccines 15, 1421-1430 (2016
132. Stanley, D. A., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126-1129 (2014
133. De Santis, O., et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect. Dis. 16, 311-320 (2016
134. Ledgerwood, J. E., Sullivan, N. J., Graham, B. S. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N. Engl. J. Med. 373, 776 (2015
135. Jones, S. M., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786-790 (2005
136. Marzi, A., et al. Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349, 739-742 (2015
137. Safronetz, D., et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736 (2015
138. Lukashevich, I. S., et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79, 13934-13942 (2005
139. Lukashevich, I. S. Advanced vaccine candidates for Lassa fever. Viruses 4, 2514-2557 (2012
140. Zapata, J. C., et al. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol. J. 10, 52 (2013